Laurus Labs Limited (NSE:LAURUSLABS)
2,472.50
+102.50 (4.32%)
Nov 9, 2026, 10:46 AM IST
Laurus Labs Revenue
Laurus Labs had revenue of 22.06B INR in the quarter ending September 30, 2026, with 33.44% growth. This brings the company's total for the last twelve months to 78.23B, up 23.03% year-over-year. In the fiscal year ending March 31, 2026, Laurus Labs had annual revenue of 68.13B with 22.67% growth. That makes Laurus Labs the 8,523rd largest company in the world by revenue and 336th in India.
Revenue (ttm)
78.23B
Revenue Growth
+23.03%
P/S Ratio
16.16
Revenue / Employee
11.08M
Employees
7,059
Market Cap
1.34T
Revenue by Geography
- outside India 45.69B 67.1%
- India 22.44B 32.9%
Fiscal year ended Mar 31, 2026 See the full Laurus Labs breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 68.13B | 12.59B | 22.67% |
| Mar 31, 2025 | 55.54B | 5.13B | 10.18% |
| Mar 31, 2024 | 50.41B | -10.00B | -16.55% |
| Mar 31, 2023 | 60.41B | 11.05B | 22.39% |
| Mar 31, 2022 | 49.36B | 1.22B | 2.54% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aurobindo Pharma | 369.13B |
| Zydus Lifesciences | 303.78B |
| Cipla | 279.89B |
| Glenmark Pharmaceuticals | 158.38B |
| Mankind Pharma | 153.79B |
| Alkem Laboratories | 150.81B |
| Divi's Laboratories | 112.30B |
| Ipca Laboratories | 104.70B |
Laurus Labs News
- 10 days ago - Laurus Labs Q2 net profit surges 126% backed by growth in CDMO, affordable medicines businesses - The Times of India
- 10 days ago - Laurus Labs to acquire 52% stake in Hyderabad-based SI&C Resins for ₹32.5 crore - The Times of India
- 10 days ago - Laurus Labs to acquire 60% stake in Canadian biotech company Galenvs Sciences - The Times of India
- 10 days ago - Laurus Labs Transcript: Q2 26/27 - Transcripts
- 10 days ago - Laurus Labs Quarterly report: Q2 2027 - Filings
- 10 days ago - Laurus Labs Slides: Q2 2027 - Filings
- 25 days ago - Laurus Labs invests $11.3 million in KRKA Pharma JV - The Times of India
- 2 months ago - Top stocks to buy today: Stock market recommendations for August 28, 2026 - check list - The Times of India